4 completed, 2 recruiting, 2 unknown. 8 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Recruiting 2, Unknown 2 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow CART-19: new trials by email Literature Review of CART-19 trials Research Report on CART-19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma CART-19 - Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | University of Sao Paulo | 81 | 2024-03-21 | 2024-12-09 |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 396 | 2023-06-12 | 2026-10-15 |
| CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) CART-19 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 15 | 2017-10-18 | 2023-11-29 |
| CART-19 Cells For MRD Positive CD19+ ALL CART-19 - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Unknown | Fujian Medical University | 20 | 2016-11-01 | 2017-01-23 |
| Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia CART-19 - Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options | Phase 2 | Completed | University of Pennsylvania | 42 | 2014-02-27 | 2023-06-22 |
| Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas CART-19 - Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas | Phase 2 | Completed | University of Pennsylvania | 63 | 2014-02-05 | 2023-06-22 |
| Dose Optimization Trial of CD19 Redirected Autologous T Cells CART-19 - Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL | Phase 2 | Completed | University of Pennsylvania | 42 | 2013-01-02 | 2023-06-22 |
| Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma CART-19 - B Cell Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 73 | 2011-08-17 | 2020-03-23 |
Lymphoma, Non-Hodgkin (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Recurrence (1)
University of Pennsylvania (4) · Fujian Medical University (1) · SWOG Cancer Research Network (1) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (1) · University of Sao Paulo (1)
United States (5) · China (2) · Brazil (1)
Noelle Frey, MD (2) · Brian T Hess (1) · Diego V Cle, MD, PhD, MBA (1) · Jianda Hu, 86-13959169016 (1) · Stephan A Grupp, MD,PhD (1) · Stephen Schuster, MD (1) · Xiaowen Tang, Ph.D. (1)
PMID 25317870, PMID 26813675, PMID 27632680, PMID 29226764, PMID 30178481, PMID 31076448, PMID 31815579, PMID 34515338, PMID 42341302, PMID 42575986
U10CA180888 (1)